Design considerations for tumour-targeted nanoparticles
Open accessAbstract
Inorganic/organic hybrid nanoparticles are potentially useful in biomedicine, but to avoid non-specific background fluorescence and long-term toxicity, they need to be cleared from the body within a reasonable timescale. Previously, we have shown that rigid spherical nanoparticles such as quantum dots can be cleared by the kidneys if they have a hydrodynamic diameter of approximately 5.5 nm and a zwitterionic surface charge. Here, we show that quantum dots functionalized with high-affinity small-molecule ligands that target tumours can also be cleared by the kidneys if their hydrodynamic diameter is less than this value, which sets an upper limit of 5-10 ligands per quantum dot for renal clearance. Animal models of prostate cancer and melanoma show receptor-specific imaging and renal clearance within 4 h post-injection. This study suggests a set of design rules for the clinical translation of targeted nanoparticles that can be eliminated through the kidneys.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Threshold for rapid renal excretion is about 5.5 nm; hydrodynamic diameters of prepared nanoparticles need to be larger than this size.
“Due to the threshold for rapid renal excretion being about 5.5 nm, the hydrodynamic diameters of the prepared nanoparticles need to be larger than this size [168–170].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [170]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710 · see citing works
Quantum Dots for Live Cells, in Vivo Imaging, and Diagnostics
Michalet, X., Pinaud, F. F., Bentolila, L. A., Tsay, J. M., Doose, S., Li, J. J., Sundaresan, G., Wu, A. M., Gambhir, S. S., & Weiss, S. (2005) · Science · doi:10.1126/science.1104274 · Cited by 7,794 · see citing works
Quantum dot bioconjugates for imaging, labelling and sensing
Medintz, I. L., Uyeda, H. T., Goldman, E. R., & Mattoussi, H. M. (2005) · Nature Materials · doi:10.1038/nmat1390 · Cited by 6,236 · see citing works
In vivo cancer targeting and imaging with semiconductor quantum dots
Gao, X., Cui, Y., Levenson, R. M., Chung, L. W. K., & Nie, S. (2004) · Nature Biotechnology · doi:10.1038/nbt994 · Cited by 4,775 · see citing works
Renal clearance of quantum dots
Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476 · see citing works
Self-citationNanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233 · see citing works
The use of nanocrystals in biological detection
Alivisatos, A. P. (2003) · Nature Biotechnology · doi:10.1038/nbt927 · Cited by 3,006 · see citing works
In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags
Qian, X., Peng, X.-H., Ansari, D. O., Yin-Goen, Q., Chen, G. Z., Shin, D. M., Yang, L., Young, A. N., Wang, M. D., & Nie, S. (2008) · Nature Biotechnology · doi:10.1038/nbt1377 · Cited by 2,201 · see citing works
The potential environmental impact of engineered nanomaterials
Colvin, V. L. (2003) · Nature Biotechnology · doi:10.1038/nbt875 · Cited by 2,161 · see citing works
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer
Harisinghani, M. G., Barentsz, J., Hahn, P. F., Deserno, W. M., Tabatabaei, S., van de Kaa, C. H., de la Rosette, J., & Weissleder, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022749 · Cited by 1,971 · see citing works
Polymer conjugates as anticancer nanomedicines
Duncan, R. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1958 · Cited by 1,956 · see citing works
Immunological properties of engineered nanomaterials
Dobrovolskaia, M. A., & McNeil, S. E. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.223 · Cited by 1,823 · see citing works
Bioconjugated quantum dots for in vivo molecular and cellular imaging☆
SMITH, A., Duan, H., Mohs, A. M., & Nie, S. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.03.015 · Cited by 1,196 · see citing works
Peptide-Labeled Near-Infrared Quantum Dots for Imaging Tumor Vasculature in Living Subjects
Cai, W., Shin, D., Chen, K., Gheysens, O. S., Cao, Q., Wang, S. X., Gambhir, S. S., & Chen, X. S. (2006) · Nano Letters · doi:10.1021/nl052405t · Cited by 949 · see citing works
Cell-specific targeting of nanoparticles by multivalent attachment of small molecules
Weissleder, R., Kelly, K., Sun, E. Y., Shtatland, T., & Josephson, L. (2005) · Nature Biotechnology · doi:10.1038/nbt1159 · Cited by 898 · see citing works
New Technologies for Human Cancer Imaging
Frangioni, J. V. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3065 · Cited by 800 · see citing works
Self-citationCompact Cysteine-Coated CdSe(ZnCdS) Quantum Dots for in Vivo Applications
Liu, W., Choi, H. S., Zimmer, J. P., Tanaka, E., Frangioni, J. V., & Bawendi, M. G. (2007) · Journal of the American Chemical Society · doi:10.1021/ja073790m · Cited by 415 · see citing works
Self-citationSentinel Lymph Node Imaging Using Quantum Dots in Mouse Tumor Models
Ballou, B. T., Ernst, L. A., Andreko, S. K., Harper, T. F., Fitzpatrick, J. A. J., Waggoner, A. S., & Bruchez, M. P. (2007) · Bioconjugate Chemistry · doi:10.1021/bc060261j · Cited by 344 · see citing works
Tissue- and Organ-Selective Biodistribution of NIR Fluorescent Quantum Dots
Choi, H. S., Ipe, B. I., Misra, P., Lee, J. H., Bawendi, M. G., & Frangioni, J. V. (2009) · Nano Letters · doi:10.1021/nl900872r · Cited by 305 · see citing works
Self-citationTanaka, E., Choi, H. S., Fujii, H., et al. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9194-6 · Cited by 262 · see citing works
Self-citationHamad, I. M., Hunter, A. C., Szebeni, J., & Moghimi, S. M. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.08.276 · Cited by 253 · see citing works
Development of aliphatic biodegradable photoluminescent polymers
Yang, J. Y., Zhang, Y., Gautam, S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900004106 · Cited by 234 · see citing works
Chen, K., Li, Z., Wang, H., Cai, W., & Chen, X. S. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0860-8 · Cited by 212 · see citing works
Quantum Dots for In Vivo Small-Animal Imaging
Bentolila, L. A., Ebenstein, Y., & Weiss, S. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.053561 · Cited by 206 · see citing works
Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation
Chen, X., Park, R. J.-H., Shahinian, A. H., et al. (2004) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2003.07.003 · Cited by 203 · see citing works
Humblet, V., Lapidus, R. S., Williams, L. R., et al. (2005) · Molecular Imaging · doi:10.2310/7290.2005.05163 · Cited by 88 · see citing works
Liver Function Assessment by Drug Metabolism
Barstow, L., & Small, R. E. (1990) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1990.tb02584.x · Cited by 48 · see citing works
Translating in vivo diagnostics into clinical reality
Frangioni, J. V. (2006) · Nature Biotechnology · doi:10.1038/nbt0806-909 · Cited by 45 · see citing works
Self-citationMatsumura, Y., Oda, T., & Maeda, H. (1987) · PubMed · Cited by 40 · see citing works
McAfee, J. G., Subramanian, G., Schneider, R. F., et al. (1985) · PubMed · Cited by 18 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Delivery of Molecular and Nanoscale Medicine to Tumors: Transport Barriers and Strategies
Chauhan, V. P., Stylianopoulos, T., Boucher, Y., & Jain, R. K. (2011) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-061010-114300 · Cited by 597 · see citing works
Lipid nanoparticles enabling gene therapies: from concepts to clinical utility
Kulkarni, J. A., Cullis, P. R., & van der Meel, R. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0721 · Cited by 592 · see citing works
Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities
Li, L., Hu, S., & Chen, X. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.031 · Cited by 415 · see citing works
Nanotechnology for protein delivery: Overview and perspectives
Yu, M., Wu, J., Shi, J., & Farokhzad, O. C. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.012 · Cited by 410 · see citing works
Modulating Pharmacokinetics, Tumor Uptake and Biodistribution by Engineered Nanoparticles
Arvizo, R. R., Miranda, O. R., Moyano, D. F., Walden, C. A., Giri, K., Bhattacharya, R., Robertson, J. D., Rotello, V. M., Reid, J. M., & Mukherjee, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024374 · Cited by 403 · see citing works
Nanoparticles for combination drug therapy
Ma, L., Kohli, M., & Smith, A. (2013) · ACS Nano · doi:10.1021/nn405674m · Cited by 367 · see citing works
Duan, X., Chan, C., Han, W., Guo, N., Weichselbaum, R. R., & Lin, W. (2019) · Nature Communications · doi:10.1038/s41467-019-09221-x · Cited by 256 · see citing works
Computed Tomography in Color: NanoK‐Enhanced Spectral CT Molecular Imaging
Pan, D., Roessl, E., Schlomka, J., Caruthers, S. D., Senpan, A., Scott, M. J., Allen, J. S., Zhang, H., Hu, G., Gaffney, P. J., et al. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201005657 · Cited by 178 · see citing works
Targeted Delivery of Nanoparticles to Ischemic Muscle for Imaging and Therapeutic Angiogenesis
Kim, J., Cao, L., Shvartsman, D., Silva, E. A., & Mooney, D. J. (2011) · Nano Letters · doi:10.1021/nl103812a · Cited by 150 · see citing works
Tang, Y., Han, S., Liu, H., Chen, X., Huang, L., Li, X., & Zhang, J. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.07.087 · Cited by 147 · see citing works
Protein nanocages that penetrate airway mucus and tumor tissue
Huang, X., Chisholm, J., Zhuang, J., Xiao, Y., Duncan, G., Chen, X., Suk, J. S., & Hanes, J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705407114 · Cited by 131 · see citing works
Skajaa, T., Zhao, Y., van den Heuvel, D. J., Gerritsen, H. C., Cormode, D. P., Koole, R., van Schooneveld, M. M., Post, J. A., Fisher, E. A., Fayad, Z. A., et al. (2010) · Nano Letters · doi:10.1021/nl1037903 · Cited by 76 · see citing works
Qi, B., Crawford, A. J., Wojtynek, N. E., Talmon, G. A., Hollingsworth, M. A., Ly, Q. P., & Mohs, A. M. (2020) · Theranostics · doi:10.7150/thno.40688 · Cited by 18 · see citing works
- Authors
- Choi, H. S., Liu, W., Liu, F., Nasr, K., Misra, P., Bawendi, M. G., & Frangioni, J. V.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Massachusetts Institute of Technology (US)
- Corresponding author
- Frangioni, John V.
- Venue
- Nature Nanotechnology
- Published
- 2009-11-01
- Volume
- 5
- Issue
- 1
- Pages
- 42-47
- ISSN
- 1748-3387 (ISSN-L)
- 1748-3395
- PMC
- PMC2797834
- OpenAlex
- W2034383333
- Cited by
- 754
- References
- 30
- Citations by year
- 2026: 20 · 2025: 17 · 2024: 17 · 2023: 20 · 2022: 35 · 2021: 23 · 2020: 47 · 2019: 50 · 2018: 53 · 2017: 63 · 2016: 61 · 2015: 70 · 2014: 51 · 2013: 71 · 2012: 65
- FWCI
- 25.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Nanotechnology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- PMC
- Funders
- National Institutes of Health (5p50gm068762-10, 5u54ca119349-05)
- National Cancer Institute (1U54 CA119349, U54 CA-119349, R01CA115296)
- National Institute of General Medical Sciences (GM 68762, P50-GM068762)
- National Institute of Biomedical Imaging and Bioengineering (R33EB000673)
- Topics
- Physical Sciences › Materials Science › Materials Chemistry › Quantum Dots Synthesis And Properties
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- quantum dots, renal clearance, ligand functionalization, hydrodynamic diameter, prostate cancer, melanoma, nanoparticle toxicity
- MeSH terms
- Animals, Antigens, Surface, Diagnostic Imaging, Fluorescence, Humans, Male, Melanoma, Prostatic Neoplasms, Tissue Distribution, Selenium Compounds, Cadmium Compounds, Integrin alphaV, Integrin beta3, Glutamate Carboxypeptidase II, Quantum Dots, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
